Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Megestrol acetate: promises and pitfalls.

D J Farrar1

  • 1Center for Special Studies, New York Hospital-Cornell Medical Center, New York, USA.

AIDS Patient Care and Stds
|June 22, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Control modes of a clinical ventricular assist device.

IEEE engineering in medicine and biology magazine : the quarterly magazine of the Engineering in Medicine & Biology Society·2009
Same author

An audit of urodynamic standardization in the West Midlands, UK.

BJU international·2002
Same author

Sustained skeletal muscle power for cardiac assist devices: implications of metabolic constraints.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2001
Same author

Multicenter experience with the thoratec ventricular assist device in children and adolescents.

The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation·2001
Same author

A versatile intracorporeal ventricular assist device based on the thoratec VAD system.

The Annals of thoracic surgery·2001
Same author

A new method of monitoring recovery and weaning the Thoratec left ventricular assist device.

The Annals of thoracic surgery·2001

Effective antiretroviral therapy can prevent HIV-associated weight loss. Megestrol acetate aids in treating HIV-wasting, particularly in women, but requires careful monitoring and combination therapy for optimal results.

Area of Science:

  • Internal Medicine
  • Infectious Diseases
  • Endocrinology

Background:

  • Effective antiretroviral therapy (ART) can suppress HIV to undetectable levels.
  • While ART may prevent weight loss, a significant patient proportion still requires specific treatment for HIV-associated wasting.

Purpose of the Study:

  • To evaluate megeestrol acetate as a treatment for HIV-associated wasting.
  • To highlight its efficacy, particularly in women, and discuss optimal usage.

Main Methods:

  • Review of existing reports on megeestrol acetate for HIV-wasting.
  • Analysis of dosage ranges (400-800 mg/day) and patient monitoring.
  • Consideration of combination therapy approaches.

Main Results:

Related Experiment Videos

  • Megestrol acetate acts as an appetite stimulant, promoting weight gain primarily through increased body fat.
  • It is particularly effective in women for managing HIV-associated wasting.
  • Adverse effects necessitate close patient monitoring.

Conclusions:

  • Megestrol acetate is a valuable tool for managing HIV-associated wasting.
  • Optimal outcomes are achieved when combined with exercise and anabolic agents to preserve lean body mass.
  • Patient education on potential side effects is crucial.